ERBB2 and neoplasm: In another recent study, a single dose administration of a half-life extended sdAb targeting the human epidermal growth factor receptor 2 (HER2) conjugated to Auristatin F demonstrated excellent efficacy in vivo and led to durable tumor remissions (>124 days) [12].